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httpcense.Abstract Introduction: COPD is a common preventable and treatable disease characterized by
persistent airﬂow limitation that is usually progressive and associated with an enhanced chronic
inﬂammatory response in the airways and the lung to noxious particles or gases. Exacerbations
and co-morbidities contribute to overall severity in individual patients. Oxidative stress represents
one of the key pathogenic mechanisms in the development of COPD. MDA increased production of
interleukin (IL)-8 and tumor necrosis factor-a (TNF-a), both attract inﬂammatory cells and
increase oxidant production by these cells. Attenuation of oxidative stress would be expected to
result in reduced pulmonary damage and a decrease in local infections, contributing to attenuation
of the progression of COPD.
Aim of the study: To compare the effects of high dose NAC versus regular dose on inﬂammatory
response, oxidative stress, pulmonary functions and clinical outcome in patients with COPD acute
exacerbations.
Patients and methods: This randomized controlled study included 45 COPD acute exacerbation
patients. All patients received standard COPD exacerbation treatment and were randomly assigned
to either; control group (A) with no add on therapy, low dose group (B) received NAC 200 mg
sachets TID, high dose group (C) received NAC 400 mg sachets TID for 10 days. IL8, malondial-
dehyde (MDA), arterial blood gases and spirometric parameters were evaluated at baseline and
after treatment.292 St., New Maadi. Cairo,
L. Mohammed El Wakeel).
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52 A.M.A. El Haﬁz et al.Results: IL8 levels signiﬁcantly decreased (p< 0.001) in group C (3.47 ± 0.81), versus Group B
(5.57 ± 1.66) and group A (8.33 ± 1.69). MDA levels signiﬁcantly decreased (p< 0.001) in group
C and group B over time. Pulmonary functions (FEV1, FVC and FEV1/FVC) and partial pressure
of oxygen PaO2 signiﬁcantly improved (p< 0.001) in group C versus group B and A over time. The
P/F ratio signiﬁcantly improved (p< 0.001) in group C versus group A. No side effects were
reported with NAC administration.
Conclusion: High dose NAC improves clinical outcome of COPD exacerbation patients by ame-
liorating oxidative stress and inﬂammatory response thereby improving lung spirometry and pul-
monary oxygenation.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Open access under CC BY-NC-ND license.Introduction
COPD is deﬁned as a common preventable and treatable dis-
ease, which is characterized by persistent airﬂow limitation
that is usually progressive and associated with an enhanced
chronic inﬂammatory response in the airways and the lung
to noxious particles or gases [1].
An acute exacerbation of COPD is a sustained worsening of
a patient’s condition, from stable state and beyond normal
day-to-day variations, that is acute in the onset and necessi-
tates a change in regular medication [2]. Reduction of exacer-
bation rates is one of the main treatment goals in COPD [1].
COPD exacerbations are considered to reﬂect worsening
of the underlying chronic inﬂammation in the airways [3].
Exacerbations and co-morbidities contribute to the overall
severity in individual patients [4] this severity is correlated with
a decrease in (FEV1) the most widely used marker of disease
severity and progression [5].
Oxidative stress, deﬁned as an imbalance between in-
creased exposure to oxidant and/or decreased antioxidant
capacity, represents one of the key pathogenic mechanisms
in the development of COPD [6]. COPD patients have shown
decreased antioxidant and increased lipid peroxidation prod-
ucts in the sputum and exhaled breath condensate of patients
with COPD reﬂected in increased MDA levels which is a sen-
sitive marker of lipid peroxidation. Markers of oxidative stress
are increased even further during exacerbations of COPD, and
in patients with a very severe form of this disease [7]. Lipid
peroxidation products measured as malondialdehyde (MDA)
content correlated inversely with the degree of small airway
obstruction [8].
Kluchova et al. reported that MDA levels were signiﬁcantly
higher in patients with severe compared to patients with mod-
erate COPD and there was a signiﬁcant inverse relationship
between FEV1 and plasma MDA levels which indicate that
MDA is a good marker of severity of obstructive lung impair-
ment in patients with COPD [9].
Oxidative stress is closely linked to inﬂammation. Increased
production of interleukin (IL)-8 and tumor necrosis factor-a
(TNF-a), both attract inﬂammatory cells and increase oxidant
production by these cells. Attenuation of oxidative stress
would be expected to result in reduced pulmonary damage
and a decrease in local infections, contributing to attenuation
of the progression of COPD [10].
NAC is a thiol reducing agents, it has a mucolytic proper-
ties that degrade the three-dimensional network which forms
the mucus by reducing the disulﬁde bonds (S–S) to a sulfhydryl
(SH) bond (–SH) that no longer participates in the cross-link-ing [11]. They may act on the mucus elasticity and viscosity as
well as modulate its production and secretion facilitating the
removal of pulmonary secretions [12]. Moreover, by maintain-
ing the airway clearance, it prevents bacterial stimulation of
mucin production and hence mucus hyper-secretion [11].
Oral NAC administration results in increased plasma cys-
teine levels, ultimately leading to increases in plasma glutathi-
one (GSH) [13]. NAC exhibits both direct as well as indirect
antioxidant properties. Direct effect being due to free thiol
group, which interacts with the electrophilic group of reactive
oxygen species (ROS) [14]. Indirect antioxidant effect is related
to its role as (GSH) precursor, which serves as a central factor
in protecting against both internal and external toxic agents
[14]. The role of NAC in COPD and COPD exacerbations
has shown beneﬁt [15].
Aim of the study
The present study aimed to compare the effect of high dose
NAC administration versus standard dose on inﬂammatory
markers, oxidative stress, pulmonary oxygenation and clinical
outcome in patients with acute exacerbation of COPD and
evaluate NAC tolerability in these patients.
Patients and methods
Design
Prospective, randomized, controlled, double blinded study.
Setting
The study was conducted at the National Institute of Chest
and Allergic Diseases hospital (NICD) in Giza – Egypt.
Subjects and methods
All patients presenting to the Chest Department were assessed
for eligibility. Inclusion criteria included: (1) COPD diagnosis
with a history of P2 exacerbations/year in 2 years prior to
enrollment, (2) an age between 40 and 70 years; (3) a post-
bronchodilator FEV1/FVC <70% of predicted; (4) an FEV1
reversibility <12% of the predicted value, 15 min after 400 lg
(4 puffs) of Salbutamol; (5) and to be currently experiencing
an acute exacerbation of COPD. Exclusion criteria included;
allergy or intolerance to NAC, cystic ﬁbrosis, bronchiectasis,
history of infection or active infection by TB, history of active
peptic ulcer.
Table 1 Patients’ demographics.
Parameters Control
(n= 15)
Low dose NAC 600 mg/day
(n= 15)
High dose NAC 1200 mg/day
(n= 15)
p Value
Age (y) 55.5 ± 9.2 59.6 ± 6.6 62 ± 4.1 0.043*
Sex (male/female) Male (15) Male (15) Male (15)
Severity (grade) Severe (15) Severe (15) Severe (15)
Concomitant diseases
Hypertension (n (%)) 4 (26.7%) 6 (40%) 6 (40%)
Diabetes (n (%)) 4 (26.7%) 3 (20%) 5 (33.3%)
Smoking indices mean
(peakyear)
20.87 ± 2.58 21.53 ± 3.314 21.73 ± 3.52
* p < 0.005 is consider signiﬁcant.




(NAC 600 mg/day) (n= 15)
High dose group
(NAC 1200 mg/d) (n= 15)
p Value
FEV1 38.8 ± 1.8 38.5 ± 1.3 39.2 ± 1.9 0.554
FVC 58.1 ± 1 58.2 ± 1.3 58.1 ± 1.5 0.96
FEV1/FVC 49.7 ± 2.4 50.1 ± 1.4 50.1 ± 1.8 0.74
MDA lmol/L 2.37 ± 0.86 2.25 ± 0.95 2.58 ± 0.28 0.482
IL-8 pg/ml 5.36±.9 4.92 ± 1.04 5.67 ± 0.66 0.077
PaO2 63.1 ± 2.1 63.0 ± 2.2 63.7 ± 2.6 0.682
PaCO2 47 ± 2.3 47.1 ± 2.1 46.7 ± 1.5 0.872
P/F 273.8 ± 40.2 283.4 ± 40.9 298.5 ± 36.3 0.232
O2 device a b c d a b c d a b c d
6 5 4 0 8 4 1 2 10 4 0 1
PH 7.37 ± 0.03 7.36 ± 0.03 7.37 ± 0.03 0.459
SaO2 90.6 ± 1.8 90.5 ± 2.5 90.6 ± 1.4 0.979
a, Patient on room air; b, patient on 1 L/min nasal canula; c, patient on 2 L/min nasal canula; d, venturi mask; MDA, malondialdehyde; IL8,
interleukin 8; PaO2, partial pressure of oxygen; PaCO2, partial pressure of carbon dioxide; P/F ratio, partial pressure of oxygen/fraction of
inspired oxygen; SaO2, oxygen saturation; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; NAC, N-acetylcysteine.
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A, B or C. Group A (control); received COPD exacerbation
standard treatment according to GOLD 2011 [4]. Group B; re-
ceived standard treatment + low dose NAC (600 mg/ day).
Group C; received standard treatment + high dose NAC
(1200 mg/day), all for a continuous 10 days period.
Drug administration
Administered NAC sachets (200 mg each) were obtained from
SEDICO pharmaceutical company (Egypt). Standard COPD
exacerbation medication included; Systemic glucocorticoids
oral prednisolone 30–40 mg/day, short acting B2 agonist
(SABA) salbutamol and antibiotics [4].
The study was approved by the hospital Ethics Committee
and patients gave an informed consent. COPD was diagnosed
based on the GOLD criteria [4].
Baseline evaluation included; history taking, physical exam-
ination, routine laboratory workup, and chest radiography.
The following parameters were evaluated for all patients on
admission (T0), and after 10 days (T10) of treatment and these
included; spirometric pulmonary function tests (SPFTs), MDA
levels in the plasma by spectrophotometery [16], arterial blood
gases (ABGs) and IL8 levels in the plasma. Patients were mon-
itored for incidence of NAC related side effects and drug
interactions.Statistical analysis
Data were analyzed using SPSS version 17. Nominal and ordi-
nal data were presented as percentage, and continuous data
were presented as means ± SD. ANOVA test with repeated
measures was used to compare means between the groups over
time. p-value <0.05 was considered signiﬁcant for all statisti-
cal test results. Pearson’s correlation coefﬁcient was done to
correlate between various parameters.
Results
Forty-ﬁve acute COPD exacerbation patients matched the
inclusion criteria and were included and randomized to one
of 3 groups A–C with 15 patients in each group.
Patients’ demographics are presented in (Table 1).
On admission, there was no signiﬁcant difference between
the 3 groups in any of the following parameters; FEV1%,
FVC%, FEV1/FVC ratio, MDA levels, IL-8 levels, PaO2,
PaCO2, P/F ratio, pH, SaO2 (Table 2). Control group age
was signiﬁcantly lower (55.5 ± 9.2) than high dose group
(62 ± 4.1), (p< 0.05). All patients included in the study were
male patients with severe COPD. Mean Smoking index (pack-
year) was not signiﬁcantly different between 3 groups; (con-
trol; 20.87 ± 2.58, low dose; 21.53 ± 3.314, high dose;
21.73 ± 3.52).
Figure 1 MDA levels in the 3 groups before & after treatment.
MDA_0: MDA on admission; MDA_10: MDA after treatment.
Figure 2 FEV1/FVC values in the 3 groups before & after
treatment. FEV1/FVC_0: FEV1/FVC at admission, FEV1/
FVC_10: FEV1/FVC after treatment.
Figure 3 P/F ratio levels in the 3 groups before & after
treatment. P/F_0: P/F at admission; P/F_10: P/F after treatment.
Figure 4 IL-8 ratio levels in the 3 groups before & after treatment.
IL-8_0: IL-8 at admission, IL-8_10: IL-8 after treatment.
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cantly decreased (p< 0.001) in group C (3.47 ± 0.81), versus
Group B (5.57 ± 1.66) and group A (8.33 ± 1.69). Plasma
MDA levels signiﬁcantly decreased (p< 0.001) in group C
and group B over time. Pulmonary functions (FEV1%,
FVC% and FEV1/FVC%) and partial pressure of oxygen
PaO2 signiﬁcantly improved (p< 0.001) in group C versus
group B and A over time. The P/F ratio signiﬁcantly improved(p< 0.001) in group C versus group A. No side effects were
reported with NAC administration (see Figs. 1–4 and Table 3).
Discussion
The major ﬁndings of the current study includes: (a) NAC
treatment signiﬁcantly decreased elevated MDA levels versus
control; (b) high dose NAC was superior to low dose & control
groups in improving SPFTs; (c) IL-8 levels decreased signiﬁ-
cantly in high dose NAC group; (d) PaO2 signiﬁcantly
improved in the high dose group versus low dose group and
Table 3 Parameters after treatment in the 3 groups.
Parameter Control (n= 15) Low dose (n= 15) High dose (n= 15) p Value p Values
Between groups Time Interaction
FEV1 43.5 ± 2.7 45 ± 1.3 48.5 ± 2.7 <0.001
* <0.001 <0.001 <0.001
FVC 63.9 ± 3 65.7 ± 2.2 68.3 ± 1.1 <0.001 * <0.001 <0.001 <0.001
FEV1/FVC 52 ± 2.6 54.9 ± 1.3 57.3 ± 1.3 <0.001
* <0.001 <0.001 <0.001
(MDA) lmol/L 2.86 ± 0.88 1.82 ± 0.97 1.55 ± 0.47 0.056 0.056 <0.001 <0.001
IL-8 pg/ml 8.33 ± 1.69 5.57 ± 1.66 3.47 ± 0.81 <0.001* <0.001 0.031 <0.001
PaO2 71.8 ± 2.1 74.5 ± 3.6 78.3 ± 3.2 <0.001
* <0.001 <0.001 <0.001
PaCO2 44.1 ± 3 43.2 ± 4.2 43.5 ± 3 0.807 0.807 <0.001 0.734
P/F 343.3 ± 30.1 350.9 ± 45 382.7 ± 26.5 0.025* 0.025 <0.001 0.424
PH 7.43 ± 0.02 7.41 ± 0.04 7.41 ± 0.02 0.055 0.055 <0.001 0.305
SaO2 93 ± 1.3 93.4 ± 1.8 94.2 ± 1 0.508 0.508 <0.001 0.088
* p < 0.005 is consider signiﬁcant.
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group versus control group.
In the current study, at baseline the three groups were com-
parable in their demographic characteristics regarding sex and
disease severity, except for the control group whose age was
signiﬁcantly lower than the high dose group. Patients included
were all males between the age of 40–70 years, complying with
the GOLD guidelines, that reported a COPD prevalence that
was higher in males, smokers and an age over 40 years than
non-smokers, females and an age under 40 [4,17].
While exacerbations of COPD are considered to reﬂect
worsening of the underlying chronic inﬂammation and is asso-
ciated with disease severity, this is usually correlated with a de-
crease in (FEV1) the most widely used marker of disease
severity and progression [5].
At baseline the 3 groups’ SPFTs were low, in accordance
with other studies of COPD exacerbations that reported a seri-
ous negative impact on patient’s lung volume, and a doubling
in the rate of decline in the FEV1 [5].
In the current study, after 10 days of treatment, NAC
1200 mg group showed the
highest improvement in lung functions as reﬂected by a sig-
niﬁcant increase in all SPFTs versus low dose or control
groups which is similar to the results of Zuin and Colleagues
(2005), that reported an increase in FEV1 only in NAC
1200 mg group after 5 days and an increase in FEV1 after
10 days in both low and high NAC groups [15].
Moreover, in the study by Stav and Raz (2009), in moder-
ate-to-severe COPD patients, treatment with NAC 1200 mg,
improved patients’ physical performance and endurance time
to exercise [18]. FVC was higher especially after exercise in
the NAC treated group compared to placebo. In contrast to
the study by Decramer et al. (2005), that has failed to show
an improved effect with NAC treatment [19], a meta-analysis,
documented that the use of NAC signiﬁcantly reduced the
numbers of exacerbations in COPD patients [20].
Alveolar oxygenation is reﬂected by P/F ratio, which is said
to be an independent factor for predicting whether avoiding
intubation will be possible [21]. In the current study, the three
groups were comparable at baseline in their P/F ratio, after
treatment with NAC, the high dose group showed a signiﬁcant
increase in P/F ratio relative to low dose and control groups
indicating an improvement in alveolar oxygenation.
Increased oxidative stress plays a role in enhancing the
inﬂammatory response leading to progression and increasingthe severity of COPD [22]. COPD patients are subjected to en-
hanced oxidative stress and increased level of MDA which is a
sensitive marker of lipid peroxidation [9]. Moreover, exacerba-
tions of COPD lead to further elevations in various markers of
oxidative stress [7].
In our study, prior to treatment, MDA levels were high in
the 3 groups when measured in plasma indicating a high oxida-
tive stress burden in COPD exacerbation patients, coinciding
with other studies [9,23], that showed that MDA levels were
linked to COPD severity.
After 10 days of NAC treatment, our results showed a sig-
niﬁcant decrease in MDA levels in the high and low dose
groups relative to the control, indicating that NAC administra-
tion improved the oxidative stress burden. This decline was
dose dependant as the high dose group showed a more decline
in MDA levels than the low dose yet the difference was not sig-
niﬁcant. These results are consistent with Patil and Colleagues
(2011) that showed a signiﬁcant decrease in serum MDA levels
from baseline to post-treatment levels, yet with the maximum
decline observed in the low dose group [24].
IL-8, is a pro-inﬂammatory cytokine and a potent chemoat-
tractant for neutrophils. IL-8 plays a primary role in the acti-
vation of both neutrophils and eosinophils in the airways of
COPD patients and may serve as a marker in evaluating the
severity of airway inﬂammation [25].
There is a controversy about the role of IL-8 in COPD
exacerbations, as some studies have reported increased levels
[26], whereas others have not reported this ﬁnding [27]. Qui
and Colleagues (2003), reported increased neutrophil recruit-
ment and gene expression of neutrophil chemoattractant
receptors in bronchial biopsies from patients with acute severe
COPD exacerbations compared with those with stable COPD
and non-smoking healthy subject [28].
In the present study, IL-8 levels were high in the three
groups at baseline indicating an increased inﬂammation in
COPD exacerbation patients complying with the results of
other studies [26,29], that documented high IL- 8 in COPD
exacerbation patients. Bhowmik and Colleagues, demon-
strated that patients with more frequent exacerbations have
higher baseline sputum interleukin (IL)-6 and IL-8 levels,
and these cytokines may predict the frequency of future exac-
erbations [30]. Moreover, it was shown that intubated patients
with severe exacerbations, undergo an up-regulation of gene
expression for IL-8 [28] and also a signiﬁcant correlation was
shown to exist between increased levels of systemic IL-8 and
56 A.M.A. El Haﬁz et al.enhanced peripheral muscle weakness [31], indicating that
ameliorating inﬂammatory effects induced by IL-8 might con-
tribute to a better outcome in COPD exacerbations.
In our study, the high dose group showed a signiﬁcant de-
crease in IL-8 levels after treatment as compared to their pre-
treatment values, on the contrary, the control and the low dose
group showed a signiﬁcant increase in IL8 levels after treat-
ment relative to their pre-treatment levels, indicating that high
doses may be required to efﬁciently reduce levels of inﬂamma-
tory mediators and modulate the inﬂammatory process. These
results are in accordance with the results of Zuin et al. (2005)
that reported a signiﬁcant decrease in IL-8 levels only in the
high dose group with an increase in levels in the control group
and no change in the low dose group [15].
In contrast to our results, van Overveld et al. (2005), have
demonstrated a signiﬁcant decrease in sputum IL-8 with low
dose NAC treatment [32] which elaborates that low NAC
doses may improve the inﬂammatory response in the lungs
yet might not be sufﬁcient to ameliorate the overall oxidative
stress burden.
The current study also demonstrated a highly signiﬁcant
moderate negative correlation between IL-8 levels after treat-
ment and the SPFs, indicating that ameliorating the inﬂamma-
tory response may signiﬁcantly improve lung functions and
COPD patients’ clinical outcome.
Coinciding with our results, are the results of Drost et al.
[33], that reported a linear relationship between IL-8 levels in
large airway samples and in BAL ﬂuid with the measured
FEV1/FVC ratio[33]. Conﬂicting with our results, are the re-
sults of Akbulut et al. (2009), who found no correlation be-
tween IL-8 levels and FEV1, FEV1/FVC values [29].
In our study neither low nor high dose NAC caused any
side effects except for one patient in the high dose group
who developed a 2-day duration of rhinorrhea indicating the
safety and tolerability of high dose NAC. These results were
consistent with those of Bachh et al. (2007), who observed
no side effects with low dose NAC [14] also the results of Zuin
et al. (2005), which reported that both low and high NAC are
equally well tolerated, with a report of only one adverse event
in the high dose group and two in the placebo group [15].
Stav and Raz (2009), stated that apart from mild epigastric
discomfort that was reported by a few patients in the high dose
NAC group, no other complaints or ﬁndings were recorded
[18].
Conclusion
High dose NAC improves clinical outcome of COPD exacer-
bation patients by ameliorating oxidative stress and inﬂamma-
tory response, hence improving lung spirometry and
pulmonary oxygenation.
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